The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and
economic burden in both developing and developed countries. Controlling the spread of …

More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human
pathogen, the only approved treatment remains a combination of pegylated interferon-α and …

Nucleotide analog inhibitors have shown clinical success in the treatment of hepatitis C virus
(HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA …

In (+) RNA coronaviruses, replication and transcription of the giant∼ 30 kb genome to
produce genome‐and subgenome‐size RNAs of both polarities are mediated by a cognate …

The C-terminal region of Clostridium perfringens enterotoxin (C-CPE) can bind to specific
claudins, resulting in the disintegration of tight junctions (TJs) and an increase in the …

The development of resistance to direct-acting antivirals (DAAs) targeting the hepatitis C
virus (HCV) can compromise therapy. However, mechanisms that determine prevalence and …

Described herein are structure–activity relationship studies that resulted in the optimization
of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B …

Here we report on the expression, purification and characterization of recombinant ebola
virus RNA-dependent RNA polymerase (EBOV RdRp). Active protein complexes composed …

Flavivirus protein NS5 harbors the RNA-dependent RNA polymerase (RdRp) activity. In
contrast to the RdRps of hepaci-and pestiviruses, which belong to the same family of …

Background & Aims Replication of hepatitis C virus (HCV) requires host cell factors, such as
cyclophilin A (CypA). CypA binds to HCV's nonstructural protein (NS) 5A to promote …